RRM2 and renal carcinoma: revealed that RRM2 inhibition reduced PD‐L1 levels and augmented the antitumor efficacy of αPD‐1 in renal cancer.[63] Notably, the exact association between PD‐L1 levels and PD‐1/PD‐L1 blockade therapy response in KIRC remains unclear.